Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors
复制标题
DOI：
10.1182/blood-2009-04-218651
复制
发表时间：
2009-10-29
期刊：
影响因子：
20.3
通讯作者：
Ehninger, Gerhard
中科院分区：
文献类型：
--
作者：
Hoelig, Kristina;Kramer, Michael;Ehninger, Gerhard
我们报道了3928名连续的无关干细胞捐献者的外周血干细胞动员、采集和随访的结果。在PBSC捐献后的基线、白细胞分离、1个月、6个月和每年进行前瞻性评估。在随访期间，采用回帖问卷记录不良反应。第5天CD34(+)细胞计数中位数男性为67.5个/亩L，女性为51个/亩L。骨痛和头痛是重组人粒细胞集落刺激因子最常见的副作用。23例(0.6%)需经中心静脉途径。在整个随访过程中，中性粒细胞绝对计数略低于初始基线值，但仍在正常范围内。大多数捐赠者报告健康状况良好或非常好。恶性肿瘤12例(0.3%)，其中急性髓系白血病1例，慢性淋巴细胞性白血病1例，霍奇金病2例。只有霍奇金淋巴瘤的发病率与年龄调整后的人群有显著差异。综上所述，每天7.5 mg/kg的来诺司汀动员异基因移植的造血干细胞是安全有效的。对健康的PBSC捐赠者进行长期监测对于保证PBSC动员和采集的安全标准仍然很重要。(血。2009；114：3757-3763)
We present results of peripheral blood stem cell (PBSC) mobilization, collection, and follow-up from 3928 consecutive unrelated stem cell donors. Assessments were performed prospectively at baseline, leukapheresis, 1 month, 6 months, and annually after PBSC donation. During follow-up, side effects were recorded by return post questionnaires. The median CD34(+) cell counts on day 5 were 67.5/mu L in male and 51/mu L in female donors. Bone pain and headache were the most common side effects of recombinant human granulocyte-colony stimulating factor. Central venous access was required for 23 donations (0.6%). Throughout the follow-up, the absolute neutrophil counts were slightly below the initial baseline values but remained within the normal range. The majority of the donors reported good or very good health. Malignancies occurred in 12 donors (0.3%), among whom were 1 case of acute myeloid leukemia, 1 case of chronic lymphatic leukemia, and 2 cases of Hodgkin disease. Only the incidence of Hodgkin lymphoma differed significantly from an age-adjusted population. In conclusion, 7.5 mu g/kg per day lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation. Long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection. (Blood. 2009; 114: 3757-3763)